Morningside Biopharma Advisory (MBA)

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
MBA is a biopharmaceutical incubator that brings innovative therapies rapidly to market by building a portfolio of companies around prototype assets focused on infection, immunity & inflammation. MBA is backed by Morningside Ventures who have an established and enviable reputation over its several decades of existence as an independently-minded, science-focused, life sciences investor. we have advanced some of our portfolio build through our shared services under the leadership of our internal team of highly experienced biopharma executives and entrepreneurs. Our innovative and globally sourced assets have begun to advance through discovery & into clinical development, & now form the basis of 4 companies within Morningside Ventures’ extensive portfolio of companies. MBA’s operating model provides the financial wherewithal, timing, expertise, & ability to grow our science into therapeutic opportunities with meaningful patient benefit, protected IP & large commercial market opportunity
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Artugen, Bacainn, Clear B & Epsila
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Morningside Biopharma Advisory